AstraZeneca Pharma's share price opened at ₹8,409 and was trading with a gain of over 8% at 9:43 AM. The company has announced its Q4 FY25 earnings results, showcasing significant growth across its operations and therapeutic areas. The company's robust performance has led to a substantial increase in profits and revenue, reflecting a strong strategic focus and an innovative product portfolio.
For the fourth quarter of fiscal year 2025, AstraZeneca Pharma India reported a consolidated net profit of ₹ 58.25 crore, marking a significant 48% increase compared to the same period last year.
This growth was complemented by a rise in revenue from operations, which jumped by 25.3% year-on-year to ₹480.48 crore. The company's profit before tax (PBT) also saw a notable improvement, reaching ₹84.15 crore, up from ₹54.36 crore in the corresponding quarter of the previous year.
The Chief Financial Officer and Director has highlighted that FY2024-25 was a year of significant progress, driven by a strategic focus on science, specialists, and an innovation-led portfolio. This approach has allowed AstraZeneca Pharma India to expand its impact across various therapy areas, demonstrating a commitment to delivering sustainable value.
The company's performance in Q4 contributed to a 32% rise in full-year revenue compared to the previous fiscal year.
A detailed look at the therapeutic segments reveals the drive behind this growth. The oncology segment delivered a revenue of ₹315.85 crore. This represents a substantial 31.62% increase over the same period last year, underscoring the company's strength in cancer treatments.
The biopharmaceuticals division, which includes therapies for cardiovascular, renal, metabolism, respiratory, immunology, and vaccines, also showed modest growth. Its revenue reached ₹122.74 crore, up 1.9% year on year.
The company experienced the highest growth in the rare disease segment. Revenue from this emerging area surged to ₹2 crore in Q4 FY25, a significant leap from ₹0.17 crore in Q4 FY24, highlighting the company's expanding focus in addressing unmet medical needs.
Sanjeev Panchal, Country President and Managing Director of AstraZeneca Pharma India, proudly announced a significant milestone: the company has, for the first time, crossed the ₹1,700 crore mark, equivalent to US$200 million in revenue. He emphasised that the company's success is rooted in scientific advancements, which are transforming healthcare and improving the health of individuals and society.
Read more on: L&T Final Dividend of ₹34 Record Date Tomorrow, June 3, 2025
AstraZeneca Pharma India Limited's fourth-quarter results for FY25 demonstrate a period of exceptional growth and strategic achievement. With strong performances in key therapeutic areas like oncology and rare diseases and the achievement of a significant revenue milestone, the company is well-positioned for continued success in the Indian pharmaceutical market.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.
Published on: Jun 2, 2025, 9:49 AM IST
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
